Hanui Lee, Gyeong Han Jeong, So-Yeun Woo, Hyo Jin Choi, Byung Yeoup Chung, Kyung-Bon Lee, Hyoung-Woo Bai
Nialamide is a non-selective monoamine oxidase inhibitor that was widely used as an antidepressant. However, it has been prohibited for decades in the depressive medicine market due to the adverse hepatotoxic side effects. The re-use of drugs that have been withdrawn from the market represents a promising approach for the development of novel incrementally modified drugs and, in this context, ionizing radiation can serve as a powerful tool for producing new drug candidates. The present study exposed nialamide to γ radiation at 50 kGy to obtain the novel cyclized benzylamide, nialaminosin (compound 2), along with five known compounds, 3-amino- N -benzylpropanamide (compound 3), 3-methoxy- N -benzylpropanamide (compound 4), 3-hydroxy- N -benzylpropanamide (HBPA; compound 5), N -benzylpropanamide (compound 6) and isonicotinamide (compound 7)...
May 2024: Experimental and Therapeutic Medicine